Upload
others
View
14
Download
0
Embed Size (px)
Citation preview
711
AUTHOR INDEX
Abrahamsson, T., 82Adams, Jr., James D., 37Andrews, Allen F., 231Andrews, Allen F., 238
Argenbright, Lois S., 606
Arison, Byron A., 606Ashcroft, Susan B., 583Awazu, Shoji, 341
Azria, M., 699
Bai, S. A., 495
Baillie, Thomas A., 123
Balfour, Celia, 26
Barsotti, Deborah A., 1 17Bartels, M. J., 286
Bawarshi-Nassar, Rima N., 248Bayne, W. F., 166Belanger, Pierre M., 91
Benet, Leslie Z., 414Bergman, A., 441
Bergstrom, J., 709Berk, Paul D., 677
Bertilsson, Leif,433
Bickers, David R., 360
Birch, D. W., 106Birnbaum, Linda S., 506
Black, Ann, 662Black, Brigette, 677
Blair, Ian A., 625, 634
Blaschke, Terrence F., 49Bochner, Felix, 190
Boezeman, Jan B. M., 98Boudinot, F. Douglas, 590
Bowman, T. A., 160Brady, Pamela K., 231
Brady, Pamela K., 238
Brandt, I., 441Braselton, Jr., W. E., 406
Brouwer, Kenneth R., 646, 652Brundrett, Robert B., 402
Brunner, Lane J., 54
Buck, William B., 600Bugg#{233},Christopher J. L., 275Bugg#{233},Christopher J. L., 280Buhler, Donald R., 380
Buhler, Donald R., 387Bui, Hoang, 641Bulger, William H., 487Burckart, Gilbert J., 292Burka, Leo T., 612
Callery, Patrick S., 398Callery, Patrick S., 513
Cano, Jean Paul, 197Carpenter, Hillary M., 131Cassel, Mary E., 224Cederbaum, Arthur I., 694Chang, Tsun, 662Chen, I.-W., 166
Chen, 1-Wu, 426Chen, T. H., 406Chen, Tian-Ling, 402Chisima, Susumu, 455
Chu, Chung K., 590Clark, Mary Jo, 469
Clejan, Liviu A., 694
Coan, Mary, 420Coddington, Kathleen A., 600
Colby, H. D., 709Colby, Howard D., 186Cole, S. P. C., 551
Colvin, 0. Michael, 402
Combalbert, Jean, 197Conley, Barbara A., 398Cook, C. Edgar, 153Cook, Kathleen J., 518Coon,MinorJ.,7
Coon, William W., 271Corbin, Neal, 345
Cornfield, Linda J., 26Cox, Jeffrey, W., 373
Craig, John, 345
Cravanzola, Carlo, 437
Crooks, Peter A., 180Crooks, Peter A., 248
Cunningham, Michael L., 612Curtis, Lawrence R., 131
Dahl-Puustinen, Marja-Liisa, 433Dalet, Isabelle, 197Damani, L. A., 20Dannan, Ghazi A., 387
Dannecker, R., 699Darnerud, P. 0., 441Dean, Margaret, 87
Dean, Margaret E., 579
De Clercq, E., 683
deLuna, Florencia A., 147
Dent,J., 174Dent,JohnG., 117Derancourt, Jean, 197
de Vries, Michiel H., 573Dewey,R., 174Diliberto, Janet J., 506
Domino, Edward F., 271Dore, Francois M., 91Doshi, Kokila J., 590D’Souza, Martin J., 595
Duggan, D. E., 166Dumont, Etienne, 433Duncan,C.A., 166Du Souich, Patrick, 704Dvorchik, B. H., 160
Easterling, D. E., 495Eckardt, R., 174Eddy, A. Craig, 265Egger, H., 669
Egorin, Merrill J., 398Elo, Heikki A., 690
Fabre, Gerard, 197
Fabre, Isabelle, I 97Ferguson, Ronald J., 231Ferguson, Ronald J., 238Ferraiolo, B. L., 369
Fleckenstein, Lawrence, 304
Flowers, N. Lynn, 186
Forkert, P. G., 106Forkert,P.G., 551Franzone, Jos#{233}Sebastian, 437
Fujiyoka, Toshihiro, 77
Fukazawa, H., 463
Gabriel, Steve, 656
Gallo, James M., 590Gelboin, Harry V., 360Gelboin, H. V., 551
Gibaldi, Milo, 265
Godin, C. Steven, 180
Goldstein, Robin S., 139
Greenfield, John C., 518
Grillo, Mark P., 123Grosa, Giorgio, 437
Gruenke, Larry, 345Guengerich, F. Peter, 387
Haanen, Clemens, 98
Hachiyama, Shizuko, 77Halpert, James, 26
Halpin, R. A., 166Haney, C. A., 495Hartman, Neil R., 292Hassan, Aslam S., 600
Hatzinger, Paul B., 297Hayashi, Masahiro, 341Hayden, Patrick J., 297
Heimark, Larry D., 265
Hein,DavidW.,231Hem, David W., 238
Heintz, R., 463
Hicks, James L., 662Hill,JudithM., 153Hirayama, Hiroki, 556
Hoffman, Kurt-JUrgen, 69Hofman, Gerard A., 573
Hollenbach, S., 369Hook, Jerry B., 139Hooper, Wayne D., 212Hottlet, H#{233}l#{232}n,704Hovens, Christopher M., 190
Huang, Che C., 662
Huelle, Belinda K., 304Hughes, D. M., 160Huijzer, Jeannett C., 37
Hultgren, B., 369Hussain, Anwar A., 248
Iannucci, R., 669
Ichihara, S., 463lida, Satofumi, 341Ikeda, Yurika, 77Ikenishi, Yuji, 323Inaba,T., 330
Inaba, T., 334
Ishida, Takashi, 77Ito, Kenichi, 77
Iwakawa, Seigo, 414Iwase, Yukiko, 77
Iwatani, Kouji, 323
Jacob, III, Peyton, 224
Jacobs, Natalie L., 677
Jajoo, Hemant K., 625, 634Jardine, Ian, 292Jaw, John-Yan, 26Jaw, John-Yan, 37Jeffcoat, A. Robert, 153
Johansson, Benny, 351Johnson, P. B., 709Joly, R., 463Joyce, David A., 208
Jung, Donald, 365
Kadar, Dezso, 567
Kalow, W., 334Kalow, Werner, 567
Kassam, Jeanine P., 567
Kedderis, Gregory L., 606
Kedzierski, Bogdan, 380Kedzierski, Bogdan, 387
Kelly, Colleen, 393Keohane, D., 174
Kershaw, William C., 1 17Khan, Wasiuddin A., 360Kiang, Chin-Hen, 43Kirlin,WardG., 231
Kirlin, Ward G., 238Knapp, Joseph E., 292
Kochak, G., 669Kochhar, D. M., 618Koop, Dennis R., 694Koster, Andries Sj., 573
Kovacs, J., 330Krabil, Lavern, 393Krieter, Philip A., 14
Kubiak, Teresa, 393Kuhn, Christine, 360Kumagai, Yoshito, 77
Kupfer, David, 487Kushinsky, Stanley, 43
Kuslikis, B. I., 406
Labrecque, Gaston, 91
LaBudde, John A., 625, 634
Lacy, Steven A., 481La Delfa, Ignazio, 49Lage, Gary L., I 17
Lalande, Marcel, 91Lambert, Chantal, 704
Lamontagne, Daniel, 704Lan, S. J., 532
Larson,PhilipG., 373
Lee, Carol, 43Lee, Helen, 662
Lee, Ling-Jar, 32Lee, Shi-Fueng, 414
LeMaire, M., 699Leonard, Thomas B., 1 17Levitt, M., 709
Lignell, E., 82Lim, Weng Hua, 212
712 AUTHOR INDEX
Lin, Emil T., 414Lin, Fu-Tyan, 292Lin, Jiunn H., 147Lin, Jiunn H., 221
Lin, Jiunn H., 426Lindberg, Claes, 3 1 1Linssen, Peter C. M., 98Ludden, Thomas 0., 304
Luke, David R., 54
Mangold, Donald J., 304
Marbach, P., 699
Marlowe, Carolyn. 469Mash, Eugene A., 26
Massarella, Joseph W., 473Matthews, H. B., 612
Matthews, Hewitt W., 595Maurel, Patrick, 197Maurer, G., 699Mayol, Robert F., 625, 634
McCabe, J., 369
McHugh, Teresa A., 677McMahon, Timothy F., 506
McNamara, Patrick J., 646, 652Melder, D. C., 526Menargues, A., 673
Merk, Hans F., 360Mico,B., 174
Mico,BruceA., 139
Migdalof, B. H., 532Mihashi, Kunihide, 77
Mikulski, A., 82Miller, Michael A., 304Minutella, L. M., 618
Miura, Yuji, 455
Miwa, Gerald T., 606Mizojiri, Kenji, 564Mizuma, Takashi, 341Mo, Zhengji, 49
M#{246}nkk#{228}nen,Jukka,, 690
Morrison, Brent E., 583
Muirhead, Murray R., 190Mukhtar, Hasan, 360Murray, Michael, 449
Nakagawa, Kikuko, 64
Nakagawa, Yuzo, 323
Nakajima, Yoshikazu, 323Nakano, Masayuki, 323
Nakano, Masayuki, 564Nelson, Sidney D., 355
Newton,J.F., 174
Nieuwenhuijs, J., 1
Nishimura, Merry C., 224Niwa, Toshiro, 64
Noe, Dennis A., 402
Noguchi, Hideyo, 64
Nomen, M., 673Noordhoek, Jan, 573
Northroot, Helen, 345Nouws, J. F. M., 1
Obach, R., 673O’Donnell, John P., 186
Ogolla, Fredrick, 231Ogolla, Fredrick, 238
Okuda, Hirokai, 677O’Leary,IrvingA., 518
Olovson, 5-0., 82Osawa, Yoichi, 7Otterness, Diane, 255Owens, S. Michael, 641
Pang, Sandy K., 556
Park, Sang S., 360Park,S.S., 551
Parli, C. John, 656Parnonen, Petteri, 690Passananti, G. T., 160Peet, N. P., 495Penglis, Stan, 87
Penner,J.D.,6l8Perez-Reyes, Mario, 153Persson, Kerstin, 218
Petty, Brent G., 402
Pilon, Denis, 481Pitti, R., 369
Pitts, Lawrence H., 224
Plunkett, Laura M., 641Pohorecki, Roman, 271
Pollock, Stanley H., 595
Porubcan,M.A., 532Porubek, David J., 123Potter, Barry J., 677Potts, Brian D., 656
Powis,G., 526
Prasad, Pratapa P., 365
Pruett, J. K., 495Pru#{241}onosa,J., 673Pullen, Robert H., 373
Rane, Anders, 218Rashed, Mohamed S., 355
Rayburn, William, 271Reboani, Maria Camilla, 437
Reed, Ralph L., 380Reed, Ralph L., 387Reg#{226}rdh,C.-G., 82Reidy, Gordon F., 449
Renberg, Lars, 69Rettie, Allan E., 265
Reuning, Richard H., 583Rickert, Douglas E., 481
Rikans,LoraE., 114Roberts, Alan E., 481
Robertson, P., 669Rodriguez, Lolita C., 275
Rodriguez, Lolita C., 280Ronfeld, Robert A., 542
Ronfield, Robert A., 58Roos, Claes, 31 1
Ross, David, 348Rufino, F. A., 669
Sabramanyam, Babu, 398Sadler, Albert, 348Sadler, Brian M., 153
Sakuma, Noriko, 341
Sanchez-Barona, Dawn 0. T., 304Santos, George W., 402
Scanlan, L. M., 532Schwartz, M. S., 166Schweitzer, A., 699
Sherratt, A. J., 20
Sherry, J. H., 709Simmons, Roy, 420Simonsson, Roger, 69
Smith, David E., 32
Smith, F. A., 286
Smith, Jack L., 606Snyder, Stuart, 398Somogyi, Andrew A, 190
Sood, Virendra K., 373Spahn, Hildegard, 414
Speth, Paul A. J., 98Stancato, F., 669
Starzi, Thomas E., 292
Steams, Ralph A., 606Stevens, James L., 297
Stock, Beresford, 87Stock, Beresford H., 579Streeter, Anthony J., 355
Stroh, Justin G., 58
Stubbs,R.J., 166Suba, Eric, 348
Subrahmanyam, Vangala V., 348Suganuma, Toshiyuki, 414Sugeno, Koichi, 323
Sundaram, Rajah S., 255Svensson,LeifA.,31l
Swanson, Barbara R., 208
Swanson, Steven P., 600
Swynnerton, Nollie F., 304
Szinai, I., 683Szumlanski, Carol, 255
Takeyama, Shigeyuki, 455
Tang, Bing K., 567Tarloff, Joan B., 139Tateishi, M., 463Termond, Emiel F. S., 98
Thongnopnua, Phensri, 473Tocco, Dominick J., 147Toki, Satoshi, 77
Tokuma, Y., 64Tomisawa, H., 463
Tompkins, Gregory C., 54Trager, William F., 265Trapani, Angelo J., 14
Tremaine, Larry M., 58Tremaine, Larry M., 542
Trinidad, Alma, 231Trinidad, Alma, 238
Tunek, Anders, 31 1Turner, Jr., Max J., 481Tyndale, R. F., 334
Ulm,EdgarH., 147
Ulm, Edgar H., 426
Unger, S. E., 532
Urtti, Arto, 690
Vall#{234}s,J., 673Vane, Floie M., 275Vane, Floie M., 280
van Gogh, H., 1Van Loon, Jon A., 255
van Miert, A. S. J. P. A. M., 1Venkatarmanan, Raman, 292
Verburg, Michael T., 373Vesell, E. S., 160
Vessey,M.L.,55l
Vicchio, Domenick, 513Vickers, F. F., 160Vickers, S., 166
Vogelsang, Georgia B., 402
Wachtmeister, C. A., 441
Waddell, William J., 469
Wade, Denis N., 208Wahlstr#{246}m, Agneta, 218Walle, T., 495Walle, U. K., 495
Walsh, John S., 606Wang, C. Paul, 292
Warrack, B. M., 532Watson,A.D.J., 1
Wehler, E. Klasson, 441
Weinshilboum, Richard M., 255
Weinstein, S. H., 532Welch, Willard M., 542
Wessels, Hans M. C., 98Wiley, James N., 583Wilke, T. J., 526
Wilking, H., 369
Williams, David E., 380
Williams, David E., 387Wilson, M. J., 495Woolf, Thomas F., 662Wynalda, Michael A., 373
Xu, Xin, 556
Yamamoto, T., 469Yano, Masashi, 77Yarma, R. K., 532Yerokun, Tokunbo, 231Yerokun, Tokunbo, 238Ylitalo, Pauli, 690Yodis, L. P., 174Yost, Garold S., 37
Zhu, Quan Ming, 49Ziegler, Daniel M., 380Zimmerman, Cheryl L., 473Zorbas, Mark, 641
6-Acetamidohexanal, active aldehydic metabolite, hexamethylene bisa-
cetamide, 398Acetaminophen
N-hydroxylation of 3’-hydroxyacetanilide, 355nephrotoxicity, susceptibility, middle-aged rats, 139
transport of conjugates, hepatocytes (rats), 341N-Acetylisoniazid, isoniazid and, temporal variations, pharmacokinetics
(rats), 91
N-Acetyltransferasesbladder isozymes (hamsters), 231, 238isoniazid and N-acetylisoniazid, temporal variations, pharmacokinet-
ics (rats), 91Acitretin, pharmacokinetic disposition, influence of pregnancy (rats),
646, 652Acrylonitrile, metabolism to 2-cyanoethylene oxide, liver microsomes,
lung microsomes and lung cells (rats), 481Adrenal cortex, spironolactone metabolism (guinea pigs), 186
Adrenal gland, activation of spironolactone, regional differences (guineapigs), 709
Adriamycin, pharmacokinetics, hematopoietic cells (humans), 98
Aginghepatic drug metabolism (rats), 1 14middle-aged rats, susceptibility, acetaminophen nephrotoxicity, 139
-related changes in benzyl acetate disposition (rats), 506Albumin, conjugates, pharmacokinetics, D-penicillamine (rats), 208Alcohol dehydrogenase, liver variants, variety of substrates (humans),
567Aldehyde oxidase, activities ofdrug oxidases, cultured hepatocytes (rats),
20Allyl alcohol, hepatotoxicity, enhancement by methoxyflurane (rats),
117
Amiloride, renal tubular secretion, inhibition by cimetidine (humans,
rats),190
l-Aminobenzotriazole, inhibition of 3-methylindole bioactivation
(goats), 374-Amino-N-(2,6-dimethylphenyl)benzamide, metabolism and disposi-
tion, pharmacokinetics (rats), 656Amiodarone, -digoxin interaction, reduction, hepatic uptake (rats), 704
Anthracycline, hematopoietic cell pharmacokinetics (humans), 98
Antianxiety drugsbuspirone metabolism (humans), 634buspirone metabolism (rats), 625
Anticonvulsants, 4-amino-N-(2,6-dimethylphenyl)benzamide, metabo-lism and disposition (rats), 656
Antihypertensive agents, disposition of flavodilol (rats, rabbits), 420Anti-inflammatory agents, isoxicam, in vivo metabolism (rats, dogs,
monkeys), 662
Antimycotic agents, croconazole metabolism (rabbits), 323Antioxidants, U-74006F, pharmacokinetics, perfused liver (rats), 373
Antipyrinepotent inhibitor of metabolism, fluconazole (mice), 49test (dogs, monkeys), 160
Arthritis, adjuvant, pharmacokinetic analysis, cyclosporine (rats), 595Assays
antipynne test (dogs, monkeys), 160biotransformation of etretinate (mice), 618liquid chromatography mass spectrometry, bambuterol metabolism,
liver microsomes (rats), 31 1Atenolol, metoprolol and, central nervous system kinetics (dogs), 82
Atrial natriuretic peptide, metabolism of, extraction by organs (rats), 143’-Azido-3’-deoxythymidine, 3’-azido-2’,3’-dideoxyuridine and (mice),
Bambuterol, metabolism in liver microsomes (rats), 3 1 1
Benzyl acetate, age-related changes in disposition (rats), 506
humanidentification, etretinate metabolites. 275
isolation, cyclosporine metabolites, 292novel metabolite of morphine,
yl)dihydromorphinone (guinea pigs), 77Bile duct, enterohepatic circulation, T-2 toxin metabolites (rats), 600
Biphenyl, foreign compound-metabolizing activity, hepatocytes and liverslices (humans, dogs, rats), 526
4,4’-Bipyridyl, N-methylation as toxication route (guinea pigs), 180
Bladder, N-acetyltransferase isozymes (hamsters), 23 1 , 238fJ-Blockers, atenolol and metoprolol, central nervous system kinetics
(dogs), 82Blood, human, identification, etretinate metabolites, 275Bone marrow, stimulation of bioactivation of hydroquinone, phenol,
348
Bovine growth hormone-releasing factor analog, Leu27-gGRF(l-29)NH3,
metabolic degradation, bovine and porcine plasma, 393Brain, locomotor activity, doxofylline (rats), 437Bronchodilation, doxofylline, brain and locomotor activity (rats), 437
Buspironemetabolism (humans), 634metabolism (rats), 625
Carbamic acid ester glucuronide, characterization, sertraline carbamoyl-
O-glucuronide (dogs), 58
Carbonyl sulfide, copper chelating metabolite of disulfiram, 351
Carboxylic acid, metabolic conversion of2-propylpentanal, valproic acid,513
Carcinogensbladder N-acetyltransferase isozymes (hamsters), 23 1 , 238
2,6-diaminotoluene, metabolism and disposition (rats), 612Carprofen, diastereomeric glucuronides, direct determination (humans),
414
Central nervous system, kinetics, atenolol and metoprolol (dogs), 82
CGS 16617, physiological disposition (rats, dogs, humans), 669Chlordecone, pretreatment, characterization, altered pharmacokinetics
(mice), 131
5-(2-Chlorocthyl)-2’-deoxyuridine, biotransformation (mice), 683Chronopharmacokinetics, isoniazid and N-acetylisoniazid, temporal var-
iations (rats), 91Cilastatin
dose-dependent kinetics (rats, dogs), 426insulin interaction (rats), 54
Cimetidine, inhibition, renal tubular secretion of amiloride (humans,rats), 190
Clara cells, pulmonary toxicity of trichloroethylene (mice), 106Clodronate, uptake by macrophages (mice), 690
Clotrimazole, induction of hepatic cytochrome P.450, isozyme-specificmonoclonal antibody (rats), 360
Cocaine, disposition after intravenous injection, nasal insufflation, smok-ing (humans), 153
Copper, chelating metabolite ofdisulfiram, carbonyl sulfide, 351
Croconazoleantimycotic, deimidazolation, epoxide formation in liver microsomes
(rabbits), 564
metabolism (rabbits), 3232-Cyanoethylene oxide, metabolism of acrylonitrile, liver microsomes,
lung microsomes and lung cells (rats), 481
713
590
SUBJECT INDEX
Bile
(8S)-(glutathion-S-
714 SUBJECT INDEX
Cyclosporin A, metabolism (humans), 197Cyclosporine
isolation of metabolites, human bile, 292pharmacokinetic analysis, adjuvant arthritic rats, 595
Cysteine, conjugates, multiple metabolic pathways, 297Cytochrome P-450
activities of drug oxidases, cultured hepatocytes (rats), 20
anti-3a IgG inhibition of pyrazole oxidation, liver microsomes (rab-
bits), 694
deimidazolation of antimycotic croconazole, epoxide formation, livermicrosomes (rabbits), 564
flavin-containing monooxygenase, N-oxidation, senecionine (rats), 380
hepaticbioactivation and detoxication, senecionine (rats), 387induction by clotrimazole, isozyme-specific mAb (rats), 360
hepatic monooxygenase activity, influence of phenobarbital, gestation
stages (rats), 579immunohistochemical study, monoclonal antibodies, lung (mice), 551
inactivation of liver steroid hydroxylases (rats), 26
potent inhibitor ofantipyrine metabolism, fluconazole (mice), 49rifampicin-inducible, product, P45OIIIA gene subfamily (humans), 197
selective inactivation by phencyclidine (rabbits), 7stereoselective oxidation of nilvadipine (rats, dogs), 64suicide substrates, inhibition, 3-methylindole bioactivation (goats). 37
Cytochrome P-450 PB-B, formation of inhibitory complex, isosafrole
metabolite, liver microsomes (rats), 449
Cytosol, bladder N-acetyltransferase isozymes (hamsters), 231. 238
Darier’s disease, biotransformation of etretinate (mice), 618
Daunomycin, pharmacokinetics, hematopoietic cells (humans), 98Debrisoquine monooxygenase, sparteine, variant allozymes (humans),
334
6-Desmethylnaproxen sulfate, metabolite of naproxen, human plasma,43
Deuterium, -labeled metabolite of trimebutine, metabolic pathways
(rats), 455Diabetes, experimental, elimination kinetics, diflunisal (rats), 147
2,6-Diaminotoluene, metabolism and disposition (rats), 612Dichloromethylene bisphosphonate, uptake by macrophages (mice), 690Diet, influence of nutritional status, pharmacokinetics and pharmaco-
dynamics, pentobarbital (rats), 365Diflunisal
elimination kinetics, experimental diabetes (rats), I 47protein binding, species differences, 221
Digoxin, -amiodarone interaction, reduction, hepatic uptake (rats), 704Dihydropyridine, calcium antagonist nilvadipine, stereoselective oxida-
tion, liver (rats, dogs), 64N.N’-Dimethyl-4,4’-bipyridyl ion, N-methylation as toxication route
(guinea pigs), I 80
Dimethyl sulfoxide
inhibition of urethane metabolism (mice), 469intravenously administered, tissue distribution (rats), 224
Dipeptidylpeptidase, metabolic degradation of Leu27-gGRF(l-29)NH3,
bovine and porcine plasma, 393Disulfiram, copper chelating metabolite, carbonyl sulfide, 351Doxofylline, brain and locomotor activity (rats), 437
Ehrlichia phagoct’tophila, effect on sulfadimidine pharmacokinetics(goats), 1
Epoxide, formation in liver microsomes, deimidazolation, antimycoticcroconazole (rabbits), 564
17�3-Estradiol, progesterone and, nasal absorption and metabolism (rats),
248
Ethanol, liver alcohol dehydrogenase variants, variety of substrates (hu-mans), 567
Ethiofos, disposition (monkeys), 304
Etretinate
biotransformation (mice), 618identification of metabolites
human bile, 275
human blood, 280metabolites, pharmacokinetics (dogs), 473pharmacokinetic disposition, influence of pregnancy (rats), 646, 652
Flavin, -containing monooxygenase, N-oxidation, senecionine (rats), 380
Flavodilol, disposition (rats, rabbits), 420Fluconazole, potent inhibitor ofantipyrine metabolism (mice), 49
Furosemide, renal drug transport, effect, organ perfusion (rats), 32
Fusaria, T-2 toxin metabolites, enteroheptic circulation (rats), 600
Gestation, influence of phenobarbital, hepatic monooxygenase activity(rats), 579
Glucose, cilastatin-insulin interaction (rats), 54
Glucuronidation, metabolic interaction of morphine and naloxone, liver(humans), 218
Glucuronides, diastereomeric carprofen, direct determination (humans),
414
Glutathione-S-transferase, ligandin levels, dose-related effects, phenobar-bital (rats). 677
(85)-(Glutathion-S-yl)dihydromorphinone, novel metabolite of mor-phine from bile (guinea pigs), 77
Glycine, benzyle acetate disposition, aging-related changes (rats), 506
Haloperidol reductase, liver (humans, guinea pigs), 330Haloxyfop, stereochemical inversion (rats), 286
Hematopoietic cells, anthracycline pharmacokinetics (humans), 98Hepatocytes
activities of drug oxidases, cultured hepatocytes (rats), 20covalent binding to protein, valproic acid, hepatotoxic metabolite
(rats), 123decreased foreign compound-metabolizing activity, comparison to
liver slices (humans, dogs, rats), 526metabolism in subcellular fractions, nitrogen-containing steroid (rats),
606
reduction of uptake, amiodarone-digoxin interaction (rats), 704transport of acetaminophen conjugates (rats), 341
Hepatotoxicity. allyl alcohol, enhancement by methoxyflurane (rats),117
Hexamethylene bisacetamide, active aldehydic metabolite, 398Hydrogen peroxide, oxidation of tenoxicam, leukocyte peroxidases, 463Hydroquinone, stimulation of bioactivation by phenol, bone marrow
cells, 3482’-Hydroxy-3,4,4’-trichlorocarbanilide, sulfate conjugate, hydrolytic be-
havior, 345
3’-Hydroxyacetanilide, N-hydroxylation, 355L-a-Hydroxy acid oxidase, quantitation of multiple pathways of metab-
olism, nephrotoxic cysteine conjugates, 297Hydroxybiphenyl, foreign compound-metabolizing activity, hepatocytes
and liver slices (humans, dogs, rats), 52617a-Hydroxylase, adrenal activation of spironolactone, regional differ-
ences (guinea pigs), 709E-lO-Hydroxynortriptyline, glucuronidation in liver, kidney, intestine
(humans), 4335-Hydroxytryptamine, uptake blocker sertraline, metabolism and dis-
position, (rats, dogs), 542
Hypercholesterolemia, physiological disposition oflovastatin (dogs), 166
Idazoxan, oral bioavailability (rats), 673Imipenem, dose-dependent kinetics of cilastatin (rats, dogs), 426
Immunoglobulin G, anti-3a IgG inhibition of pyrazole oxidation, livermicrosomes (rabbits), 694
Insulin, cilastatin interaction (rats), 54
Intestineglucuronidation of E-lO-hydroxynortriptyline (humans), 433
SUBJECT INDEX 715
-liver preparation, first-pass metabolism, salicylamide (rats), 556
metabolism of atrial natriuretic peptide (rats), 14
oral idazoxan bioavailability (rats), 673
phenol sulfotransferase, assay conditions, thermolabile form, 255�
systemic metabolism of 1-naphthol (rats), 573Isoniazid, N-acetylisoniazid and, temporal variations, pharmacokinetics
(rats), 91Isosafrole, metabolite, formation of inhibitory complex, cytochrome P-
450 PB-B (rats), 449
Isoxicam, in vivo metabolism (rats, dogs, monkeys), 662
Kidneydose-dependent kinetics of cilastatin (rats, dogs), 426
drug transport, effect, organ perfusion (rats), 32glucuronidation of E-l0-hydroxynortriptyline (humans), 433metabolism of atrial natriuretic peptide (rats), 14nephrotoxic cysteine conjugates, quantitation, multiple metabolic
pathways, 297pharmacokinetics, recombinant tumor necrosis factor-a (rats), 369
renal tubular secretion ofamiloride, inhibition by cimetidine (humans,
rats),190
renin inhibitor peptide, U-7 1038 disposition and metabolism (rats),
518
spironolactone metabolism (guinea pigs), 186
Leu27-bGRF(l-29)NH3, metabolic degradation, bovine and porcineplasma, 393
Leukocytes, peroxidases, oxidation of tenoxicam, hydrogen peroxide,
463Ligandin, hepatic glutathione-S.transferase activity, dose-related effects,
phenobarbital (rats), 677
Lipids, hydroxylated metabolites of 3,3’,4,4’-tetrachlorobiphenyl, excre-tion and tissue retention (mice), 441
Liver
alcohol dehydrogenase variants, variety of substrates (humans), 567cytochrome P.450 enzymes, bioactivation and detoxication, senecion-
inc (rats), 387
cytochrome P-450 induction by clotrimazole, isozyme-specific mono-
clonal antibody (rats), 360
drug metabolism as function ofage (rats), 1 14factors affecting phencyclidine biotransformation (humans), 271glucuronidation of E-lO-hydroxynortriptyline (humans), 433
haloperidol reductase (humans, guinea pigs), 330hepatic first-pass effect, oral idazoxan bioavailability (rats), 673homogenates, biotransformation of tipredane (mice, rats, humans),
532
inactivation of steroid hydroxylases, cytochrome P-450 (rats), 26-intestine preparation, first-pass metabolism, salicylamide (rats), 556metabolic interaction, morphine and naloxone (humans), 218nondeficient sparteine/debrisoquine monooxygenase, variant allo-
zymes (humans), 334
perfused, pharmacokinetics, U-74006F (rats), 373rifampicin-inducible cytochrome P.450, product, P45OIIIA gene
subfamily (humans), 197selective inactivation of cytochrome P-450, phencyclidine (rabbits), 7
slices, foreign compound-metabolizing activity, compared to hepato-
cytes (humans, dogs, rats), 526spironolactone metabolism (guinea pigs), 186
stereoselective oxidation of nilvadipine (rats, dogs), 64Liver microsomes
bambuterol metabolism (rats), 3 1 1epoxide formation, deimidazolation, antimycotic croconazole (rab-
bits),564
formation of inhibitory complex, isosafrole metabolite, cytochrome P-
450 PB-B (rats), 449hydroxylation of4,4’-methylenebis(2-chloroaniline)(dogs, guinea pigs,
rats), 406
metabolism of acrylonitrile, 2-cyanoethylene oxide (rats), 481
monooxygenase-mediated covalent binding, methoxychlor (humans,
rats), 487
oxidation, sensitivity of pyrazole to antibody, cytochrome P.450 iso-zyme (rabbits), 694
oxidative biotransformation, warfarin hydroxylation (humans), 265Lovastatin, physiological disposition (dogs), 166
Lungimmunohistochemical study of cytochrome P.450, monoclonal anti-
bodies(mice), 551metabolism of acrylonitrile, 2-cyanoethylene oxide (rats). 481toxicity oftrichloroethylene (mice), 106
LY2O1 1 16, metabolism and disposition, pharmacokinetics (rats), 656
fl-Lyase, quantitation of multiple pathways of metabolism, nephrotoxic
cysteine conjugates, 297
Macrophages. uptake of clodronate (mice), 690
Methoxychlor, monooxygenase-mediated covalent binding, liver micro-somes (rats, humans), 487
Methoxyflurane, enhancement ofallyl alcohol hepatotoxicity (rats), 1 17
a-Methylbenzylaminobenzotriazole, inhibition of 3-methylindole bioac-
tivation (goats), 37
4,4’-Methylenebis(2-chloroaniline), hydroxylation by liver microsomes
(dogs, guinea pigs, rats), 4063-Methylindole, inhibition of bioactivation, cytochrome P-450 suicide
substrates (goats), 37Methylphenobarbital, racemic, stereoselective metabolism, pharmacoki-
netics (humans), 212Metoprolol, atenolol and, central nervous system kinetics (dogs), 82Monoclonal antibodies
immunohistochemical study ofcytochrome P-450, lung (mice), 551isozyme-specific. induction ofhepatic cytochrome P.450, clotrimazole
(rats),360
Monooxygenase
activities of drug oxidases, cultured hepatocytes (rats), 20
flavin-containing, N-oxidation, senecionine (rats), 380hepatic activity, influence ofphenobarbital, gestation stages (rats), 579-mediated covalent binding of methoxychlor, liver microsomes (hu-
mans, rats), 487
Morphine
(8S-(glutathion-S-yl)dihydromorphinone, novel rnetabolite, bile
(guinea pigs), 77naloxone and, metabolic interaction, liver (humans), 218
Muscle, metabolism pf atrial natriuretic peptide (rats), 14Mutagenesis, 2,6-diaminotoluene metabolism and disposition (rats), 612
Naloxone, morphine and, metabolic interaction, liver (humans), 218Naltrexone, disposition and pharmacokinetics (monkeys), 583
l-Naphthol, systemic intestinal metabolism (rats), 573
Naproxen, 6-desmethylnaproxen sulfate as metabolite, human plasma,
43
Nephrectomy, pharmacokinetics, recombinant tumor necrosis factor-a(rats), 369
Nephrotoxicity, acetaminophen, susceptibility, middle-aged rats, 139Nilvadipine. stereoselective oxidation (rats, dogs), 64Nitrogen, -containing steroid, hepatocyte metabolism (rats), 606
Omeprazole, identification of main urinary metabolites (humans), 69
Paraquat, N-methylation as toxication route (guinea pigs), 180D-Pencillamine, pharmacokinetics of albumin conjugates (rats), 208
Pentobarbital, influence of nutritional status, pharmacokinetics, phar-macodynamics (rats), 365
Perfusion, organ, effect, renal drug transport (rats), 32
Phencyclidinefactors affecting biotransformation, human liver and placenta, 271
selective inactivation ofcytochrome P.450 (rabbits), 7
716 SUBJECT INDEX
Xenobiotics, N-methylation as toxication route (guines pigs), 180
Phenobarbital
dose-related effects, hepatic glutathione-S-transferase activity, ligandinlevels (rats), 677
influence on hepatic monooxygenase activity, gestation stages (rats),
579
Phenol, stimulation of bioactivation of hydroquinone, 348Phenol sulfotransferase, human intestinal, assay conditions, thermolabile
form, 255Placenta, factors affecting phencyclidine biotransformation (humans),
271
Plasma
bovine and porcine, metabolic degradation, Leu27-bGRF(l-29)NH3,393
6-desmethylnaproxen sulfate, metabolite of naproxen, 43Pregnancy
disposition ofaromatic retinoids (rats), 646, 652pharmacokinetics of salicylate (rats), 87
Progesterone, 17�9-estradiol and, nasal absorption and metabolism (rats),
248
2-Propentanal acetals, metabolic conversion to valproic acid, 513Propranolol, 4’-�ethylthio derivative, pharmacokinetics and metabo-
lism (dogs), 4952-n-Propyl-4-pentenoio acid, covalent binding to protein, valproic acid,
hepatocytes (rats), 123
Proteinbinding ofdiflunisal, species differences, 221covalent binding of valproic acid, hepatotoxic metabolite, hepatocytes
(rats), 123influence of nutritional status, pharmacokinetics and pharmacody-
namics, pentobarbital (rats), 365
Psoriasis, biotransformation of etretinate (mice), 618Pyrazole, oxidation, anti-3a IgG inhibition, liver microsomes (rabbits),
694
Renin, inhibitor peptide, U-7 1038 disposition and metabolism (rats),
518
Retinoids
aromaticbiotransformation, etretinate and etretin (mice), 618disposition, influence of pregnancy (rats), 646, 652
Rifampicin, -inducible liver cytochrome P.450, product, P45OIIIA gene
subfamily (humans), 197
Salicylamide, first-pass metabolism (rats), 556Salicylate, pharmacokinetics, pregnancy (rats), 87Sandostatin, disposition (rats), 699
Senecionine
bioactivation and detoxication, cytochrome P-450 enzymes, liver(rats), 387
N-oxidation, flavin-containing monooxygenase (rats), 380
Sertraline, metabolism and disposition (rats, dogs), 542Sertraline carbamoyl-O-glucuronide, characterization (dogs), 58
Sexhepatic drug metabolism as function ofage (rats), 1 14organs, metabolism, atrial natriuretic peptide (rats), 14
SK&F 86002, pharmacokinetics and metabolism (rats), 174
Skin, biotransformation ofetretinate (mice), 618
Somatostatin analogue, sandostatin disposition (rats), 699Sparteine, debrisoquine monooxygenase, variant allozymes (humans),
334Species differences, protein binding of diflunisal, 221
Spironolactone
adrenal activation, regional differences (guinea pigs), 709metabolism in target tissues (guinea pigs), 186
Steroids
adrenal activation ofspironolactone, regional differences (guinea pigs),
biotr��formation of tipredane, liver homogenates (mice, rats, hu-
mans), 532inactivation ofliver steroid hydroxylases, cytochrome P.450 (rats), 26
nitrogen-containing, hepatocyte metabolism (rats), 606Sulfadimidine, pharmacokinetics, tick-borne fever, trypanosomiasis
(goats), 1
Tegison, see Etretinate
Tenoxicam, oxidation by leukocyte peroxidases, hydrogen peroxide, 463
Terbutaline, bambuterol metabolism, liver microsomes (rats), 31 1Testes, spironolactone metabolism (guinea pigs), 1863,3’,4,4’-Tetrachlorobiphenyl, hydroxylated metabolites, excretion and
tissue retention (mice), 441Thalidomide, plasma pharmacokinetics, urinary excretion, healthy male
volunteers, 402
l-[l-(2-Thienyl)cyclohexyl]piperidine, pharmacokinetics (rats), 641Tick-borne fever, effect on sulfadimidine pharmacokinetics (goats), 1Tipredane, biotransformation in liver homogenates (mice, rats, humans),
532
Trichloroethylene, pulmonary toxicity (mice), 106Trichothecenes, enterohepatic circulation, T-2 toxin metabolites (rats),
600Trimebutine, metabolic pathways, deuterium-labeled metabolite (rats),
455
Trypanosoma brucei, effect on sulfadimidine pharmacokinetics (goats),
T-2 toxin, enterohepatic circulation of metabolites (rats), 600Tumor necrosis factor-a, recombinant, pharmacokinetics (rats), 369
U-71038, disposition and metabolism, novel renin inhibitor peptide
(rats), 518U-74006F, pharmacokinetics, perfused liver (rats), 373Urethane, inhibition of metabolism, dimethyl sulfoxide (mice), 469
Valproic acid
covalent binding to protein, hepatotoxic metabolite, hepatocytes (rats),123
metabolic conversion of 2-propylpentanal, 513
Warfarin, hydroxylation, oxidative biotransformation, human liver mi-
crosomes, 265WR-1065, disposition ofethiofos (monkeys), 304